WAYNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended October 1, 2023. Third quarter financial summary Revenues of $746.4 million, up 8.7% compared to the prior year period; up 7.4% on a constant currency basis GAAP diluted EPS […]
Tag: Teleflex
Teleflex Announces Extension of Arrow™ ErgoPack™ Complete System to Hemodialysis and Large Bore Central Venous Catheters
WAYNE, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the release of the Arrow™ ErgoPack™ Complete Kits with Hemodialysis and Large Bore catheters in the United States. This update is intended to streamline insertion workflow for clinicians and provide more […]
Teleflex Announces Quarterly Dividend
WAYNE, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2023, to shareholders of record at the close of business on […]
Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+™ Hemostatic Device Usage in Cardiac Surgical Procedures
WAYNE, Pa., Aug. 01, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+™ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a […]
Teleflex Announces Second Quarter 2023 Earnings Conference Call Information
WAYNE, Pa., July 20, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, August 3, 2023. To participate in the conference call, please utilize this link to pre-register and receive the […]
Teleflex Completes Enrollment in Percutaneous Coronary Intervention Study
WAYNE, Pa., July 19, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in the prospective multicenter RingerTM PTCA study. RingerTM PTCA is one of two clinical studies evaluating the performance of the novel RingerTM Perfusion Balloon Catheter. The RingerTM PTCA […]
Teleflex Receives FDA Clearance for the Wattson® Temporary Pacing Guidewire
Company expands Structural Heart Portfolio with the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV) WAYNE, Pa., June 07, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced […]
Teleflex Announces the Arrow® EZ-IO® Needle Is Now FDA Cleared For Use in an MRI Environment
First and Only IO Needle with MR Conditional Safety Status Labeling WAYNE, Pa., June 06, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, today announced that the Arrow® EZ-IO® Needle is the first and only Intraosseous (IO) Needle to receive […]
Teleflex Announces Quarterly Dividend
WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 15, 2023, to shareholders of record at the close of business on […]
Teleflex Reports First Quarter Financial Results and Full Year 2023 Outlook
WAYNE, Pa., May 04, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended April 2, 2023. First quarter financial summary Revenues of $710.9 million, inclusive of five extra shipping days year-over-year, up 10.8% compared to the prior year period; up 13.2% on a […]
Recent
4C Medical Secures $175M Series D Preferred Stock Financing
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Popular
- No commented posts yet